Latest news with #GBM
Yahoo
a day ago
- Business
- Yahoo
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recently reached a significant clinical milestone. The patient, with a grade 4, IDH-mutant glioma, has been in remission and surviving for 4 years having been treated with INB-200. The patient is doing well, has returned to work and has a good quality of life post-treatment with INB-200. Patient 009's clinical progress and 4-year remission far surpasses progression-free outcomes observed in other clinical trials of IDH-mutant glioma patients. 'Surviving four years without progression in newly diagnosed astrocytoma WHO4 IDH mutated is a significant achievement demonstrating the potential activity of gamma-delta T cells,' said Dr. Burt Nabors, Principal Investigator of the INB-200 trial and Vice-Chair of Research of Neurology and Director for the UAB Division of Neuro-oncology. 'This outcome further highlights the potential impact of INB-200 in one of the most aggressive, difficult-to-treat and deadly cancers.' IN8bio recently presented updated Phase 1 data from the INB-200 trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The results showed that repeated doses of INB-200 demonstrated an extended mPFS of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care Stupp protocol in newly diagnosed GBM. INB-200 is the first genetically modified gamma-delta T cell therapy evaluated in GBM and has demonstrated a favorable safety profile and signals of long-term benefit. 'We are thrilled that our study participant has reached this incredible milestone,' said William Ho, CEO and co-founder, IN8bio. 'This type of long-term survival and life changing clinical impact is exactly what we strive to achieve at IN8bio. The current standard-of-care for newly diagnosed GBM has not advanced beyond an overall survival of 14-16 months in over two decades. This is a powerful testament to what's possible when we harness the unique biology of gamma-delta T cells.' About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit FORWARD LOOKING STATEMENTS This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the ability of repeated intracranial dosing of INB-200 to extend mPFS and improve mOS in patients with GBM, including those with chemotherapy-resistant tumors; INB-200's ability to continue to be well-tolerated and show no serious toxicities beyond those typically observed with chemotherapy; INB-200's ability to improve patient outcomes and allow patients to return to work; the ability of IN8bio's DRI technology to offer a new way to treat newly-diagnosed GBM; gamma-delta T cells' ability to eliminate chemo-resistant cancer and stem cells that often survive SOC treatment; INB-200's potential as a novel direction in therapy for the treatment of solid tumor cancers like GBM; INB-200's ability to improve outcomes in ways that enhance effectiveness of treatments without adding toxicity; IN8bio's ability to achieve anticipated milestones, including the advancement of clinical development plans and receipt of regulatory approvals; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio's ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio's product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio's ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its γδ-TCE platform or DeltEx platform; the availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio's product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio's reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled 'Risk Factors' in IN8bio's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Contacts: IN8bio, McCall646.933.5603pfmccall@ Media Contact:KKH AdvisorsKimberly in to access your portfolio
Al Bawaba
01-06-2025
- Business
- Al Bawaba
GBM Enhances Cybersecurity at PRIME Health with Comprehensive Managed Detection and Response Service
Gulf Business Machines (GBM), a leading end-to-end digital solutions provider, has entered a strategic partnership with PRIME Health to deliver a comprehensive managed detection and response (MDR) service designed to enhance cybersecurity across the healthcare provider's this collaboration, GBM will deliver around-the-clock threat monitoring, rapid detection, and swift incident response to protect PRIME Health's digital environment. At the core of the collaboration are fully managed Security Information and Event Management (SIEM) and Security Orchestration, Automation, and Response (SOAR) platforms, empowering security teams with automated workflows, real-time insights, and a unified dashboard for enhanced visibility and faster addition, PRIME Health will leverage GBM's expert Digital Forensics and Incident Response (DFIR) team to rapidly investigate and contain threats, while gaining access to contextual, healthcare-specific threat intelligence. Furthermore, the partnership will help safeguard the healthcare provider's digital reputation by proactively monitoring for misuse, impersonation, and threats targeting the day-to-day operations, GBM will also provide ongoing support to strengthen PRIME Health's cybersecurity posture, ensuring continuous alignment with best practices, regulatory compliance, and evolving threat by a strong commitment to technological advancement in healthcare, the UAE's digital health market is projected to reach US$ 2.65 billion by 2030. The collaboration further taps into this opportunity by proactively identifying and mitigating cyber threats targeting patient data and medical devices, thereby contributing to safeguarding the critical healthcare ecosystem in the Rahiman, IT Director at PRIME Health, said, 'At PRIME Health, we recognize that cybersecurity is essential for ensuring operational resilience and safeguarding patient data, and preserving the trust of every individual who walks through our doors. As part of our continued pursuit of excellence, we were looking for a globally recognized provider that could deliver top-grade cybersecurity while securing our complex environment end to end so that our internal teams are free to focus on innovation and care delivery. This initiative reflects our promise of 'Personalised Care, Personally'—where every patient interaction is built on a foundation of trust and data confidentiality. With its proven reputation, strong partnerships, and local presence in the UAE, GBM is our trusted partner in supporting our security goals and compliance roadmap.'Ossama El Samadoni, General Manager of GBM Dubai, said, 'Our MDR service will enable PRIME Health to ensure uninterrupted care delivery while staying ahead of cyber threats. Our multi-layered collaboration reflects our shared commitment to building a secure and resilient healthcare environment. We are delighted to help PRIME Health demonstrate leadership in secure digital transformation, build patient trust by proactively defending sensitive health data, and strengthen their reputation as a security-conscious, future-ready healthcare provider.'PRIME Health is one of the UAE's most trusted healthcare providers, known for its commitment to medical excellence and patient-centric care. With a portfolio that includes Prime Hospital, Prime Medical Centers, Premier Diagnostic Center, Medi Prime Pharmacies, and specialized services such as Home Care and Corporate Medical Services, the company plays a vital role in the UAE's healthcare landscape. The group's leadership continues to drive innovation across clinical, operational, and digital domains. The increased use of technology in the Middle East and North Africa has created a rich playground for cybercrimes. With sophisticated and powerful cyberattacks compromising businesses at an unprecedented rate, redesigning security for the digital-first world has become a key priority for organizations, with revenue in the region's cybersecurity market projected to reach US$4.63 billion this year.
Yahoo
28-05-2025
- General
- Yahoo
Uni life 'like any other' despite brain cancer
David Izekor was just 18 and in his first year at the University of Leeds when his life took an unexpected turn. One night in 2021, he woke up feeling unwell. The next thing he remembers is waking up in a hospital bed, being told he had suffered a haemorrhagic stroke, a bleeding in the brain by the rupture of a blood vessel. The east Londoner had to undergo an emergency operation and was told he had a rare form of brain cancer, glioblastoma multiforme (GBM). Four years on, the film student has made a documentary sharing his experience. He hopes it "springboards conversations in schools or to other cancer groups to share that a diagnosis doesn't mean the end". Apart from being at university during the Covid pandemic, Mr Izekor says his life had been like any other fresher's. On the night he ended up in hospital, he says he doesn't remember anything, but his flatmate said he asked for some milk, which he then poured all over the kitchen floor in a delirium. "Then I woke up in hospital, a doctor was telling me I had a brain aneurism. I knew something wasn't right," says Mr Izekor. He was referred to a London hospital as doctors tried to find out what was causing the aneurism. "Then doctors attended a big meeting to discuss my future, without me present, there was lots of big words used so I had to go to Google and find things out - which is really scary," he says. "I received a call in the middle of the night one night. I had to have an emergency ten-hour awake operation on my brain because they'd found something in my head - so they needed to do a biopsy." Glioblastomas affect more than 3,000 people per year in the UK, with an average prognosis of 12 to 18 months, according to The Brain Tumour Charity. As a film student, Mr Izekor found a unique way to process his diagnosis - by documenting his journey through the lens of a camera. From his hospital bed, he began creating TikTok videos. "I was told 'my life is a movie' and I wanted to develop that idea," he says. "Through sharing my journey, I have had so many people share their own stories - even things like how to speak to family members about what you're going through." What began as short clips evolved into a full-length documentary titled One in Two, co-produced with his university flatmate and close friend, George Child. The film captures not only his personal experience but also the stories of others affected by glioblastoma. "In the making of my documentary I met lots of other families. "One family I filmed with, a young girl had the same cancer as me and unfortunately died. Her parents have been really supportive," says Mr Izekor. "I'm hoping that this springboards conversations in schools or to other cancer groups - to share that a diagnosis doesn't mean the end. "Your life will change, but there can be positives and I want to share that." Listen to the best of BBC Radio London on Sounds and follow BBC London on Facebook, X and Instagram. Send your story ideas to Man's brain tumour shrinks by half in therapy trial 'Glioblastoma took my fun-loving dad away' Man with terminal brain tumour welcomes new trial Brain Tumour Research charity: Glioblastoma Multiforme (GBM) The Brain Tumour Charity
The Sun
27-05-2025
- Business
- The Sun
APO concludes 67th Governing Body Meeting in Jakarta with new leadership, strategic roadmap
KUALA LUMPUR: The Asian Productivity Organization (APO) concluded its 67th Governing Body Meeting (GBM) in Jakarta on a high note, setting the course for the organisation's future through key leadership changes and strategic discussions. The annual meeting, hosted by the Government of the Republic of Indonesia from May 20 to 22, brought together over 50 delegates from member countries to chart the APO's direction amid shifting global productivity trends. The 67th GBM saw numerous important leadership transitions. APO Director for India Amardeep Singh Bhatia was elected Chair for 2025–26, taking over from APO Director for Fiji Jone Maritino Nemani, while APO Director for Indonesia Agung Nur Rohmad and APO Director for the Islamic Republic of Iran Dr Mohammad Saleh Owlia were also appointed as First and Second Vice Chairs, respectively. According to a statement, the Governing Body also re-elected Dr Indra Pradana Singawinata of Indonesia for a second term as Secretary-General from September 2025 to 2028, reflecting strong support for his leadership. Opening the session, Chair Bhatia underscored India's dedication to the APO's vision of inclusive and sustainable productivity and highlighted the progress made on developing the Green Productivity (GP) 2.0 ecosystem. His remarks emphasised India's role in strengthening institutional efficiency and innovation-driven collaboration across the region. The meeting was inaugurated by Indonesia's Minister of Manpower, Professor Yassierli, who stressed the need for collective action in response to economic uncertainty, technological change, and sustainability challenges. He praised the APO's role in fostering solidarity through shared solutions and region-specific initiatives like GP. Delegates deliberated on several key priorities, including the post-2025 vision framework, reforms to the membership contribution formula, and strengthening of the APO Secretariat's digital systems. The meeting also reviewed governance improvements based on third-party assessments, reaffirming the APO's commitment to transparency and accountability. Milestones announced included the accreditation of the Development Academy of the Philippines to operate the Productivity Specialist certification scheme and the expansion of Indonesia's national certification body. These developments mark progress in building a regional workforce aligned with productivity standards. The GBM also welcomed observers from the United Nations Industrial Development Organization and the Republic of Uzbekistan, signalling the APO's growing engagement with international and nonmember stakeholders. The session concluded with a celebratory announcement from Chair Bhatia confirming that India will host the 68th Governing Body Meeting in 2026, continuing its leadership in regional productivity advancement.
The Sun
27-05-2025
- Business
- The Sun
APO ends 67th meet in Jakarta with new leaders, roadmap
KUALA LUMPUR: The Asian Productivity Organization (APO) concluded its 67th Governing Body Meeting (GBM) in Jakarta on a high note, setting the course for the organisation's future through key leadership changes and strategic discussions. The annual meeting, hosted by the Government of the Republic of Indonesia from May 20 to 22, brought together over 50 delegates from member countries to chart the APO's direction amid shifting global productivity trends. The 67th GBM saw numerous important leadership transitions. APO Director for India Amardeep Singh Bhatia was elected Chair for 2025–26, taking over from APO Director for Fiji Jone Maritino Nemani, while APO Director for Indonesia Agung Nur Rohmad and APO Director for the Islamic Republic of Iran Dr Mohammad Saleh Owlia were also appointed as First and Second Vice Chairs, respectively. According to a statement, the Governing Body also re-elected Dr Indra Pradana Singawinata of Indonesia for a second term as Secretary-General from September 2025 to 2028, reflecting strong support for his leadership. Opening the session, Chair Bhatia underscored India's dedication to the APO's vision of inclusive and sustainable productivity and highlighted the progress made on developing the Green Productivity (GP) 2.0 ecosystem. His remarks emphasised India's role in strengthening institutional efficiency and innovation-driven collaboration across the region. The meeting was inaugurated by Indonesia's Minister of Manpower, Professor Yassierli, who stressed the need for collective action in response to economic uncertainty, technological change, and sustainability challenges. He praised the APO's role in fostering solidarity through shared solutions and region-specific initiatives like GP. Delegates deliberated on several key priorities, including the post-2025 vision framework, reforms to the membership contribution formula, and strengthening of the APO Secretariat's digital systems. The meeting also reviewed governance improvements based on third-party assessments, reaffirming the APO's commitment to transparency and accountability. Milestones announced included the accreditation of the Development Academy of the Philippines to operate the Productivity Specialist certification scheme and the expansion of Indonesia's national certification body. These developments mark progress in building a regional workforce aligned with productivity standards. The GBM also welcomed observers from the United Nations Industrial Development Organization and the Republic of Uzbekistan, signalling the APO's growing engagement with international and nonmember stakeholders. The session concluded with a celebratory announcement from Chair Bhatia confirming that India will host the 68th Governing Body Meeting in 2026, continuing its leadership in regional productivity advancement.
